Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

e drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at www.lorusthera.com.

CONTACT: Lorus Therapeutics Inc., Dr. Saeid Babaei, (416) 798-1200 ext.490, ir@lorusthera.com

Ticker Symbol: (Toronto:LOR.),(AMEX:LRP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:12/15/2014)... , Dec. 15, 2014 As medical device ... Product Labeling) markup language standard, content teams have a ... skills to work with the standard. Starting January 2015, ... three webinars on the benefits and the critical aspects ... will be facilitated by Howard Shatz , DCL,s ...
(Date:12/15/2014)... MINNEAPOLIS , Dec. 15, 2014   ... ), one of the nation,s largest and most ... of its business units, DaVita Clinical Research ... capabilities to further expand its extensive clinical research ... chronic kidney disease (CKD) and end-stage renal disease ...
(Date:12/15/2014)... LONDON and BOSTON , ... the leading GPCR structure-guided drug discovery and development company, ... patents in the United States ... of these patents in the US significantly strengthens the ... the major pharmaceutical markets. The suite of ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
... proud to announce its conference keynote speakers include: Centers ... CBS Evening News Anchor Katie Couric; U.S. ... U.S. Secretary of Commerce Gary Locke. Each will address ... leaders in Washington, D.C. October 18-20 during AdvaMed ...
... Arlington Medical Resources (AMR), a provider of premier ... finds that more than half of all European inpatients ... Sanofi-Aventis,s Clexane (marketed as Lovenox in the U.S. and ... The European Hospital Anticoagulant Market Guide is a ...
Cached Medicine Technology:AdvaMed 2010 Keynote Speakers Announced 2AdvaMed 2010 Keynote Speakers Announced 3European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... 26 As the voice of the global ... Organizations (ACRO) had the honor of presenting before ... 26th, 2009 in Tokyo. ACRO Chair Derek Winstanly, ... and ACRO Executive Director Douglas Peddicord, Ph.D. addressed ...
... (PHILADELPHIA) Researchers from Thomas Jefferson University have identified ... in the growth and migration of prostate cancer cells, ... in the American Journal of Pathology . , ... of the protein when compared to normal prostate cells, ...
... Feb. 26 On Monday, March 2, the ... to become "The Healthiest Company in Green Bay." The firm ... them at that goal.The 30-person agency is collaborating with Health ... ( www.hatwork.com ). The title of "Healthiest Company in Green ...
... Physicians Offers Secure Message Capability to Facilitate ... Human Science, Inc. (HSI), a Rockville ... launch of an innovative software service that ... care in a secure environment. PatientCarenet.Org ...
... monitoring, and biostatistics for several early-stage clinical trials and registries ... ... Clinipace , a growing clinical research solutions company, today announced that ... aggregate, more than $2.8 million., , ,With a focus on emerging ...
... Feb. 26 Orthopaedic surgeon Michael L. Parks, MD, ... American Academy of Orthopaedic Surgeons (AAOS) ( ... Vegas. He will serve the Academy as Member-at-Large ... specializes in the reconstruction of arthritic conditions affecting the ...
Cached Medicine News:Health News:ACRO Presents at Japan CRO Association Commemorative Symposium 2Health News:Proepithelin encourages cell growth and migration in prostate cancer 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 3Health News:Human Science, Inc. Launches PatientCarenet.Org 2Health News:Human Science, Inc. Launches PatientCarenet.Org 3Health News:Clinipace Recently Awarded $2.8 Million to Manage Three New Clinical Projects 2Health News:Michael L. Parks, MD, Elected to the American Academy of Orthopaedic Surgeons Board of Directors 2
... Pulse Oximeters are high performance, easy-to-use ... proven signal processing to track even ... with Oxismart Advanced Signal Processing and ... identify electronic and optical noise, as ...
The Model 5340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 340DT is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
... The Model 130 has expanded memory capabilities ... has memory to retain oxygen saturation and pulse ... modes to best suit your needs:, ,1. ... minutes of information for a single patient, making ...
Medicine Products: